Max@Home FY26 gross revenue rises 23% to Rs 263 crore
Key highlights
- Max@Home FY26 gross revenue rose 23% to Rs 263 crore from Rs 212 crore in FY25.
- Max@Home reported more than 5,000 daily billed transactions across 16 specialised services as of September 30, 2026.
- Max@Home recorded Rs 165 crore of gross revenue in H1 FY27.
- India’s home healthcare market is forecast to grow from USD 6.4 billion in 2025 to USD 16.8 billion in 2033.
powered by IRIS

Max@Home reported FY26 gross revenue of Rs 263 crore, up 23% from Rs 212 crore in FY25, while its operating scale exceeded 5,000 daily billed transactions. The homecare business also reported Rs 165 crore of gross revenue in H1 FY27 and offered 16 specialised services through a team of more than 2,000 people as of September 30, 2026.
Know Max Healthcare Institute inside out
Results, valuation, peers and who's buying, in one view.
How fast did Max@Home grow gross revenue?
Max@Home increased gross revenue by Rs 51 crore to Rs 263 crore in FY26 from Rs 212 crore in FY25, which the presentation marks as 23% growth. The FY26 outcome was also Rs 193 crore above the Rs 70 crore recorded in FY21. Management describes the FY19-to-FY26 revenue trajectory as a compound annual growth rate, or CAGR, of more than 20% over six years.
Revenue rose in every disclosed full year after FY21, climbing from Rs 112 crore in FY22 to Rs 139 crore in FY23, Rs 172 crore in FY24, Rs 212 crore in FY25 and Rs 263 crore in FY26. The annual increase widened from Rs 27 crore between FY22 and FY23 to Rs 33 crore between FY23 and FY24, Rs 40 crore in FY25 and Rs 51 crore in FY26. The presentation attributes this expansion to the scale-up of direct-to-customer services.
Max@Home reported Rs 165 crore in H1 FY27, compared with Rs 263 crore for the whole of FY26. The half-year figure was Rs 67 crore below the FY25 full-year total of Rs 212 crore, but it does not establish a full-year FY27 result. The source does not disclose FY27 revenue guidance, a transaction target, profitability, margins or revenue by individual service.
What is Max@Home’s operating scale and service mix?
Max@Home reported more than 5,000 daily billed transactions across 16 specialised services, with a team of more than 2,000 people as of September 30, 2026. The reported team includes support and outsourced personnel. Its 24x7 customer support operates alongside services ranging from critical care and nursing to pathology, pharmacy and medical equipment.
The 16 listed offerings include patient attendants, doctor visits, physiotherapy, dialysis, immunization, mother and child care and medical rooms. Max@Home also provides X-ray at home, electrocardiogram, or ECG, and Holter monitoring at home, sleep studies and arterial blood gas, or ABG, testing. This mix combines clinical care, diagnostics, rehabilitation, equipment and medicine-related services under the same homecare operation.
Max@Home is accredited by the Quality & Accreditation Institute, or QAI, which the presentation identifies as a member of the International Society for Quality in Health Care, or ISQua. The source does not state how the more than 5,000 daily transactions are split among the 16 services, how many patients are active, or the direct-to-customer share of total transactions. It nevertheless identifies direct-to-customer service expansion as the mechanism behind the reported revenue growth.
Got a follow-up? Ask IRIS
How does Max@Home’s growth compare across the disclosed periods?
Max@Home’s FY26 revenue of Rs 263 crore was 3.8 times its FY21 revenue of Rs 70 crore, showing a materially larger business following the FY21 low point. Revenue had been Rs 77 crore in FY19 before falling to Rs 70 crore in FY21, then increased by Rs 42 crore to Rs 112 crore in FY22. The disclosed data show a continuous annual rise from FY21 through FY26.
The FY26 increase of Rs 51 crore was the largest absolute annual increase in the disclosed sequence from FY22 onward. It exceeded the Rs 40 crore increase in FY25, the Rs 33 crore increase in FY24 and the Rs 27 crore increase in FY23. While the presentation reports a 23% FY26 growth rate, it does not provide comparable annual transaction volumes, staffing costs or revenue per billed transaction to explain the changing absolute additions.
H1 FY27 revenue of Rs 165 crore represented about 63% of FY26 revenue, but H1 FY27 covers only six months. The September 30, 2026 snapshot provides the more than 5,000 daily billed transactions and 2,000-plus team figures, whereas the revenue table reports the H1 FY27 amount. The presentation provides no prior-period transaction or headcount figures, so operating-scale growth cannot be quantified across the same years as revenue.
How large is the home healthcare market cited for Max@Home?
Max@Home operates in an Indian home healthcare market estimated at USD 6.4 billion in 2025 and forecast by Grand View Research to reach USD 16.8 billion in 2033. The presentation calculates this as 2.6 times growth and a CAGR of about 12.8% between 2025 and 2033. It also cites home healthcare as accounting for about 3.6% of total health spending in India, compared with about 8.3% in the United States.
The presentation identifies ageing as one of the market’s drivers, with India’s population aged 60 and above projected to rise from 149 million in 2022 to 347 million in 2050. It also cites an estimated 93 million diabetes cases by 2030, more surgeries and greater post-operative care at home. These are sector-demand indicators rather than measures of Max@Home’s market share or customer base.
Technology-led remote monitoring and at-home diagnostics, along with rising disposable incomes, are also cited as growth drivers. The source does not disclose Max@Home’s share of the USD 6.4 billion 2025 market, a competitor comparison, or a target share of the USD 16.8 billion forecast market in 2033. It also does not state whether its 16 services will expand further.
Conclusion
Max@Home’s FY26 gross revenue of Rs 263 crore, up Rs 51 crore from FY25, indicates that the homecare operation has built a larger revenue base while reporting more than 5,000 daily billed transactions. Its 16-service offering spans critical care, nursing, diagnostics, pharmacy, equipment and rehabilitation, supported by a team of more than 2,000 people as of September 30, 2026.
What to watch next is the progression from Rs 165 crore of gross revenue in H1 FY27 as Max@Home continues its stated direct-to-customer service scale-up. The source projects the Indian home healthcare market to increase from USD 6.4 billion in 2025 to USD 16.8 billion in 2033, but does not disclose a Max@Home FY27 revenue target, transaction target, margin target or market-share target.


